Background/aim: Genetic polymorphism of CYP2D6 shows diverse pharmacokinetic and pharmacodynamic variation. Therefore, the present work was designed to study the variation in therapeutic responses to metoprolol (MP) in stage 1 hypertensive patients and also aims to verify the association of CYP2D6*4 polymorphism and response variation in an Indian population for the first time.
Materials and methods:Clinically, a total of 119 hypertensive patients and 116 healthy individuals as controls were included. Patients were treated with MP extended release 25 mg tablets once daily for 2 weeks. Reduction in systolic blood pressure, diastolic blood pressure, and pulse rate were recorded before and after the treatment. For genotyping, genotypes of 89 hypertensive patients and 71 healthy controls were investigated for CYP2D6*4 polymorphism.Results: Based on reduction in systolic blood pressure, 26% of the patients did not respond to the MP treatment. Of the patients that responded, 28% responded very slowly, 35% (19 males, 23 females) responded moderately, and 12% (8 males, 6 females) showed a good response to MP. For genotype analysis, we pooled 89 hypertensive patients and 71 controls. No association was found between CYP2D6*4 polymorphism and MP response.
Conclusion:We found no relationship between MP response and CYP2D6*4 genotype in an Indian population in our study.
Celecoxib loaded tristearin lipid nanoparticles (CEL‐TS‐LN) formulation was prepared by micro emulsion technique. The prepared CEL‐TS‐LN formulations were characterized by photon correlation spectroscopy (PCS), Zeta potential, transmission electron microscopy (TEM), in vitro release kinetics, In vivo toxicity and pharmacokinetics; and Freund's adjuvant‐induced arthritic studies were conducted. The mean diameter of the CEL‐TS‐LN was about 188 nm; the particles had spherical morphology and an amorphous nature. In vitro drug release study of CEL‐TS‐LN revealed sustained drug release of 62% for 36 hrs; and the drug release was found to follow zero order and Fickian diffusion mechanism. The biochemical and haematology reports of in vivo toxicity studies revealed that CEL‐TS‐LN does not exhibit any toxic symptoms on vital organs and could be safe. With 88% percent inhibition of edema, serum biochemical parameters of CEL‐TS‐LN treated animal groups showed significant difference (p < 0.05) compared to arthritic control (without treatment). In conclusion, the results clearly suggested that CEL‐TS‐LN facilitated sustained release enhanced bioavailability and improved therapeutic efficiency of the encapsulated celecoxib drug.
Practical applications: In this paper we stress the importance of solid lipid nanoparticles for oral delivery. We also discuss the feasibility of large scale production of celecoxib loaded tristearin lipid nanoparticles (CEL‐TS‐LN) by micro emulsion technique for industrial application. Celecoxib (CEL) has been recommended as oral use for the treatment of rheumatoid arthritis (RA). Low oral bioavailability and long term oral administration of CEL produces severe gastrointestinal side effects. CEL‐TS‐LN holds promise for safe, improved bioavailability and enhanced therapeutic efficiency in the treatment of RA.
Successfully incorporated celecoxib into tristearin solid lipid Nanoparticles (CEL‐TS‐LN).The optimized CEL‐TS‐LN preparation was exhibited spherical morphology, amorphous nature, maximum entrapment efficiency and sustained release of celecoxib. CEL‐TS‐LN does not exhibit any toxic symptoms, enhanced bioavailability and therapeutic efficiency in In Vivo.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.